Sandbox:Rina Ghorpade: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(9 intermediate revisions by the same user not shown)
Line 1: Line 1:
"[[User:Rina Ghorpade|Rina Ghorpade,MD]][mailto:rina.ghorpade@gmail.com]"
{| style="font-size: 85%;"
! style="width: 80px; background: #4479BA; text-align: center;" colspan="2" |{{fontcolor|#FFF|Disease}}
! style="width: 80px; background: #4479BA; text-align: center;" |{{fontcolor|#FFF|Organism}}
! style="width: 80px; background: #4479BA; text-align: center;" |{{fontcolor|#FFF|Vector}}
! style="width: 720px; background: #4479BA; text-align: center;" | {{fontcolor|#FFF|Symptoms}}
|-
| style="font-size: 14px; background: #7d7d7d; text-align: center;" colspan="2" | {{fontcolor|#FFF|'''Bacterial Infection'''}}
|
|
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;" colspan="2" | ''[[Borreliosis]] ([[Lyme disease|Lyme Disease]])'' <ref name="Lyme CDC”">Lyme Disease Information for HealthCare Professionals. Centers for Disease Control and Prevention (2015).  http://www.cdc.gov/lyme/healthcare/index.html Accessed on December 30, 2015</ref>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | ''[[Borrelia burgdorferi]]'' sensu lato complex and ''[[Borrelia mayonii|B. mayonii]]''
| style="background: #F5F5F5; padding: 5px; text-align: center;" | ''[[I. scapularis]]'', ''[[I. pacificus]]'', ''[[I. ricinus]]'', and ''I. persulcatus''
| style="background: #DCDCDC; padding: 5px;" |[[Erythema migrans]], flu-like illness([[fatigue]], [[fever]]), [[Lyme arthritis]], [[neuroborreliosis]], and [[carditis]].
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;" rowspan="2" | ''[[Relapsing Fever]]'' <ref name="TBRF CDC”">Relapsing Fever Information. Centers for Disease Control and Prevention (2015).  http://www.cdc.gov/relapsing-fever/ Accessed on December 30, 2015</ref>
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Tick-borne relapsing fever (TBRF):
| style="background: #F5F5F5; padding: 5px; text-align: center;" | ''Borrelia duttoni'', ''Borrelia hermsii'', and ''Borrelia parkerii''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |''Ornithodoros'' species
| style="background: #DCDCDC; padding: 5px;" rowspan="2" | Consistently documented high [[fevers]], flu-like illness, [[headaches]], [[myalgia|muscular soreness]] or [[joint pain]], [[altered mental status]], [[painful urination]], [[rash]], and [[rigors]].
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;" |Louse-borne relapsing fever (LBRF) :
| style="background: #F5F5F5; padding: 5px; text-align: center;" | ''[[Borrelia recurrentis]]''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |''[[Pediculus humanus]]''
|-
| style="font-size: 14px; background: #7d7d7d; text-align: center;" colspan="2" | {{fontcolor|#FFF|'''Typhus (Rickettsia)'''}}
|
|
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;" colspan="2" | ''[[Rocky Mountain Spotted Fever]]''
| style="background: #F5F5F5; padding: 5px; text-align: center;" | ''[[Rickettsia rickettsii]]''
| style="background: #F5F5F5; padding: 5px; text-align: center;" | ''[[Dermacentor variabilis]]'', [[Dermacentor andersoni]]
| style="background: #DCDCDC; padding: 5px;" | [[Fever]], [[altered mental status]], [[myalgia]], [[rash]], and [[headaches]].
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;" colspan="2" |  ''[[Helvetica Spotted Fever]]'' <ref name="RMSF CDC”">Rocky Mountain Spotted Fever Information. Centers for Disease Control and Prevention (2015).  http://www.cdc.gov/rmsf/  Accessed on December 30, 2015</ref>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | ''Rickettsia helvetica''
| style="background: #F5F5F5; padding: 5px; text-align: center;" | ''[[Ixodes ricinus]]''
| style="background: #DCDCDC; padding: 5px;" | [[Rash]]: spotted, red dots. Respiratory symptoms ([[dyspnea]], [[cough]]), [[myalgia|muscle pain]], and [[headaches]].
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;" colspan="2" | ''[[Ehrlichiosis Anaplasmosis|Ehrlichiosis (Anaplasmosis)]]'' <ref name="Ehrlichiosis CDC”">Disease index General  Information (2015). http://www.cdc.gov/parasites/babesiosis/health_professionals/index.html Accessed on December 30, 2015</ref>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | ''Ehrlichia chaffeensis, Ehrlichia ewingii''
| style="background: #F5F5F5; padding: 5px; text-align: center;" | ''[[Amblyomma americanum]], [[Ixodes scapularis]]''
| style="background: #DCDCDC; padding: 5px;" | [[Fever]], [[headache]], [[chills]], [[malaise]], [[myalgia|muscle pain]], [[nausea]], [[confusion]], [[conjunctivitis]], or [[rash]] (60% in children and 30% in adults).
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;" colspan="2" | ''[[Tularemia]]'' <ref name="Tulameria CDC”">Rocky Mountain Spotted Fever Information. Centers for Disease Control and Prevention (2015).  \http://www.cdc.gov/tularemia/index.html  Accessed on December 30, 2015</ref>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | ''[[Francisella tularensis]]''
| style="background: #F5F5F5; padding: 5px; text-align: center;" | [[Dermacentor andersoni|''Dermacentor andersoni'']]'', [[Dermacentor variabilis]]''
| style="background: #DCDCDC; padding: 5px;" | Ulceroglandular, [[glandular]], oculoglandular, oroglandular, pneumonic, typhoidal.
|-
| style="font-size: 14px; background: #7d7d7d; text-align: center;" colspan="2" | {{fontcolor|#FFF|'''Viral Infection'''}}
|
|
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;" colspan="2" | Tick-borne [[meningoencephalitis]] <ref name="TBE CDC”">General Disease Information (TBE). Centers for Disease Control and Prevention (2015).  http://www.cdc.gov/vhf/tbe/ Accessed on December 30, 2015</ref>
| style="background: #F5F5F5; padding: 5px; text-align: center;" | ''TBEV virus''
| style="background: #F5F5F5; padding: 5px; text-align: center;" | ''[[Ixodes scapularis]]'', ''[[I. ricinus]]'', ''I. persulcatus''
| style="background: #DCDCDC; padding: 5px;" | Early Phase: Non-specific symptoms including [[fever]], [[malaise]], [[anorexia]], [[myalgia|muscle pains]], [[headaches]], [[nausea]], and [[vomiting]]. Second Phase: [[Meningitis]] symptoms, [[headache]], [[stiff neck]], [[encephalitis]], [[drowsiness]], sensory disturbances, and potential [[paralysis]].
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;" colspan="2" | [[Colorado tick fever|Colorado Tick Fever]] <ref name="GenTickDis CDC”">General Tick Deisease Information. Centers for Disease Control and Prevention (2015).  http://www.cdc.gov/coloradotickfever/index.html Accessed on December 30, 2015</ref>
| style="background: #F5F5F5; padding: 5px; text-align: center;" |  ''CTF virus''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |  ''[[Dermacentor andersoni]]''
| style="background: #DCDCDC; padding: 5px;" |Common symptoms include [[fever]], [[chills]], [[headache]], [[body aches]], and [[lethargy]]. Other symptoms associated with the disease include [[sore throat]], [[abdominal pain]], [[vomiting]], and a skin [[rash]]. A biphasic [[fever]] is a hallmark of Colorado Tick Fever and presents in nearly 50% of infected patients.
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;" colspan="2" | [[Crimean-Congo Hemmoragic Fever|Crimean-Congo Hemorrhagic Fever]]
| style="background: #F5F5F5; padding: 5px; text-align: center;" |  ''[[CCHF virus]]''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |  '' Hyalomma marginatum'', ''Rhipicephalus bursa''
| style="background: #DCDCDC; padding: 5px;" |Initially infected patients will likely feel a few of the following symptoms: [[headache]], high [[fever]], [[back pain|back]] and [[joint pain]], [[stomach pain]], [[vomiting]], flushed face, red throat [[petechiae]] of the [[palate]], and potentially changes in mood as well as sensory perception.
|-
| style="font-size: 14px; background: #7d7d7d; text-align: center;" colspan="2" | {{fontcolor|#FFF|'''Protozoan Infection'''}}
|
|
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;" colspan="2" | [[Babesiosis]] <ref name="Babesiosis CDC”">Babesiosis. Centers for Disease Control and Prevention (2015). http://www.cdc.gov/parasites/babesiosis/disease.htmlAccessed December 8, 2015.</ref>
| style="background: #F5F5F5; padding: 5px; text-align: center;" |  ''[[Babesia microti]], [[Babesia divergens]], Babesia equi''
| style="background: #F5F5F5; padding: 5px; text-align: center;" |  ''[[Ixodes scapularis]],  ''[[I. pacificus]]


| style="background: #DCDCDC; padding: 5px;" |Non-specific flu-like symptoms.
==Differentiating SWS from other neuro-cutaneous syndromes==
|}
 
 
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
[Differential dx1]
[Differential dx2]
[Differential dx3]
 
Epidemiology and Demographics
The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].
Age
Patients of all age groups may develop [disease name].
[Disease name] is more commonly observed among patients aged [age range] years old.
[Disease name] is more commonly observed among [elderly patients/young patients/children].
Gender
[Disease name] affects men and women equally.
[Gender 1] are more commonly affected with [disease name] than [gender 2].
The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.
Race
There is no racial predilection for [disease name].
[Disease name] usually affects individuals of the [race 1] race.
[Race 2] individuals are less likely to develop [disease name].
 
 
Risk Factors
Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
 
 
Natural History, Complications and Prognosis
 
 
The majority of patients with [disease name] remain asymptomatic for [duration/years].
Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].
 
 
Diagnosis
Diagnostic Criteria
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
[criterion 1]
[criterion 2]
[criterion 3]
[criterion 4]
Symptoms
[Disease name] is usually asymptomatic.
Symptoms of [disease name] may include the following:
[symptom 1]
[symptom 2]
[symptom 3]
[symptom 4]
[symptom 5]
[symptom 6]
 
 
Physical Examination
Patients with [disease name] usually appear [general appearance].
Physical examination may be remarkable for:
[finding 1]
[finding 2]
[finding 3]
[finding 4]
[finding 5]
[finding 6]
 
Laboratory Findings
There are no specific laboratory findings associated with [disease name].
A [positive/negative] [test name] is diagnostic of [disease name].
An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
 
 
Imaging Findings
There are no [imaging study] findings associated with [disease name].
[Imaging study 1] is the imaging modality of choice for [disease name].
On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
[Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
Other Diagnostic Studies
[Disease name] may also be diagnosed using [diagnostic study name].
Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
 
 
 
Treatment
Medical Therapy
There is no treatment for [disease name]; the mainstay of therapy is supportive care.
The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
[Medical therapy 1] acts by [mechanism of action 1].
Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
Surgery
Surgery is the mainstay of therapy for [disease name].
[Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
[Surgical procedure] can only be performed for patients with [disease stage] [disease name].
 
 
Prevention
 
 
There are no primary preventive measures available for [disease name].
Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

Latest revision as of 23:44, 12 June 2020

Differentiating SWS from other neuro-cutaneous syndromes

[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as: [Differential dx1] [Differential dx2] [Differential dx3]

Epidemiology and Demographics The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide. In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location]. Age Patients of all age groups may develop [disease name]. [Disease name] is more commonly observed among patients aged [age range] years old. [Disease name] is more commonly observed among [elderly patients/young patients/children]. Gender [Disease name] affects men and women equally. [Gender 1] are more commonly affected with [disease name] than [gender 2]. The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1. Race There is no racial predilection for [disease name]. [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].


Risk Factors Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].


Natural History, Complications and Prognosis


The majority of patients with [disease name] remain asymptomatic for [duration/years]. Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3]. If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. Common complications of [disease name] include [complication 1], [complication 2], and [complication 3]. Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].


Diagnosis Diagnostic Criteria The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1] [criterion 2] [criterion 3] [criterion 4] Symptoms [Disease name] is usually asymptomatic. Symptoms of [disease name] may include the following: [symptom 1] [symptom 2] [symptom 3] [symptom 4] [symptom 5] [symptom 6]


Physical Examination Patients with [disease name] usually appear [general appearance]. Physical examination may be remarkable for: [finding 1] [finding 2] [finding 3] [finding 4] [finding 5] [finding 6]

Laboratory Findings There are no specific laboratory findings associated with [disease name]. A [positive/negative] [test name] is diagnostic of [disease name]. An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name]. Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].


Imaging Findings There are no [imaging study] findings associated with [disease name]. [Imaging study 1] is the imaging modality of choice for [disease name]. On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3]. [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3]. Other Diagnostic Studies [Disease name] may also be diagnosed using [diagnostic study name]. Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].


Treatment Medical Therapy There is no treatment for [disease name]; the mainstay of therapy is supportive care. The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2]. [Medical therapy 1] acts by [mechanism of action 1]. Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration]. Surgery Surgery is the mainstay of therapy for [disease name]. [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name]. [Surgical procedure] can only be performed for patients with [disease stage] [disease name].


Prevention


There are no primary preventive measures available for [disease name]. Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3]. Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].